SSG
CPIX icon

Summit Securities Group’s Cumberland Pharmaceuticals CPIX Stock Holding History

Summit Securities Group’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-100
Closed -$1K – 445
2013
Q2 		$1K Buy
+100
New +$498 ﹤0.01% 532

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KIM
Kestrel Investment Management San Mateo, California $167M AUM 20.81% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Summit Securities Group's CPIX Position: Q3 2013 in Review

Summit Securities Group sold out of Cumberland Pharmaceuticals (CPIX) in Q3 2013, closing a stake of 100 shares — an estimated $1K sold.

Summit Securities Group first reported a position in CPIX in Q2 2013 and held it in 1 quarter. The position peaked at $1K in Q2 2013. 45 funds tracked by Wall St. Rank hold CPIX as of Q3 2013.

  • Summit Securities Group reported no remaining Cumberland Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 100 Cumberland Pharmaceuticals shares in Q3 2013, an estimated $1K.
  • Summit Securities Group first reported a position in Cumberland Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's Cumberland Pharmaceuticals position peaked at $1K in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.